CureVac NV (WBO:CVAC) Debt-to-Revenue : 0.46 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

CureVac NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €5.01 Mil. CureVac NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €36.82 Mil. CureVac NV's annualized Revenue for the quarter that ended in Dec. 2023 was €90.27 Mil. CureVac NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.46.

CureVac NV Debt-to-Revenue Historical Data

The historical data trend for CureVac NV's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Debt-to-Revenue Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

4.55

0.62

0.28

0.62

0.78

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.90	1.44	1.34	0.64	0.46

Competitive Comparison of CureVac NV's Debt-to-Revenue

For the Biotechnology subindustry, CureVac NV's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where CureVac NV's Debt-to-Revenue falls into.

CureVac NV Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

CureVac NV's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.005	+	36.819)	/	53.758
	=	0.78

CureVac NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.005	+	36.819)	/	90.268
	=	0.46

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

CureVac NV Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of CureVac NV's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.